Parkinson disease is second most frequently occurring neurodegenerative disease which is characterized by the progressive loss of dopaminergic neurons.
Global Parkinson Disease Drug Biomarkers Insight 2028 Report Highlights:
- Global Parkinson’s Disease Antibodies Market Opportunity: > USD 8 Billion
- Parkinson’s Disease Clinical Trials Insight: > 300 Drugs In Trials
- Parkinson’s Disease Biomarkers Sourced During Clinical Trials
- Parkinson’s Disease Insight By Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report Sample:
http://biomarkersinsights.com/parkinson-disease-biomarkers-and-clinical-trials-insight-2028
Parkinson disease is second most frequently occurring neurodegenerative disease which is characterized by the progressive loss of dopaminergic neurons. The pathology of Parkinson disease is highly complex and consists of combination of genetics, epigenetics and environmental factors. Most of the symptoms associated with the development of disease generally appear at advanced stage where most of the dopaminergic neurons have been already damaged. Therefore, in order to provide a better clinical intervention and treatment, there is unmet need for the identification of novel biomarkers for the early diagnosis of the disease. At the same time, potential biomarkers can also be used to monitor the progress of the disease. Biomarkers, as indicators of normal physiological or pathological processes, are always involved in disease mechanisms.
To date, several motor symptoms of bradykinesia, resting tremor and muscle rigidity are considered as the most significant and direct diagnostic marker for Parkinson disease. Further for the early diagnosis of disease, many non-motor features, including hyposmia, rapid eye movement (REM) sleep behavior disorder, and constipation have also gained considerable interest among research studies. In addition to these clinical biomarkers, researchers have also identified several potential biochemical markers found in blood, saliva, cerebrospinal fluid (CSF) and biopsies. Mitochondrial dysfunction, oxidative stress, Lewy body’s formation, neuroinflammation and other mechanisms have gained the maximum interest as they are involve in the physiology of the disease.
Further, neuroimaging methodologies have also become a mature biomarker for the nigrostriatal neurodegeneration by analyzing the potential structure, ultrastructural, or perfusion pattern changes in parkinson. An increasing number of neuroimaging technologies can be used to detect early changes in Parkinson disease patients and assess progression of the disease, less susceptible to the effects of subjectivity and drugs. These biomarkers have entered the clinical trial and most of them are used as surrogate outcomes for investigating the biological efficacy of a treatment. Apart from this, other biomarkers including microRNA, peptides, and genetic biomarkers have also been identified which are present in early stages of clinical trials.
In addition to this, several ongoing research studies have been exploring new approaches to discover novel biomarkers for Parkinson disease. However, the high complexity of the disease etiology and physiology, there is need for comprehensive identification of signaling pathways which aid in better understanding of the disease and development of more effective biomarkers. The advent of omic technology including genomics, transcriptomics, proteomics and metabolomics are also being applied in the study of Parkinson disease biomarkers, which will drive the growth of market during the forecast period.
As per our analysis, the global Parkinson disease biomarker market will surpass US$ 8 Billion by 2028 which is mainly attributed to the increase in prevalence of the disease globally. Further, presence of potential pipeline products, increased research and active government support is also expected to drive the growth of the market during the forecast period. The introduction of affordable biomarker testing, growing demand for non-invasive diagnostic technologies, and rise in number of clinical trials are also expected to drive the growth of market during the forecast period.
This report on global Parkinson disease biomarkers market report provides holistic understanding of the market along with market sizing, forecast, drivers, challenges, and competitive landscape. Our report provides comprehensive analysis on the approved biomarkers for Parkinson disease drugs. Apart from this, in-depth analysis on the ongoing clinical trials in biomarkers associated with novel targeted drugs in development by various phases is also mentioned in the report. The major companies mentioned in the report are Amgen, Roche, Pfizer, Gilead Sciences, GlaxoSmthKline, and others.
Contact:
Preeti Dureja
Research Partner
Biomarkers Insights
www.biomarkersinsights.com